X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gil Blum - Needham & Company, LLC - Analyst : Thank you very much, Paula. (Conference Instructions) So maybe a couple from us. Talking about WHIM specifically and considering you're getting a little closer to the commercial stage, should we expect rare disease pricing on a driver like this as a benefit to patients sufficiently high?

Question: Gil Blum - Needham & Company, LLC - Analyst : That makes sense. So we talked a little bit about chronic neutropenia and, maybe I'm off here a little bit, but another place that G-CSF is used is chemo-induced neutropenia. Any thoughts on that treatment population?

Question: Gil Blum - Needham & Company, LLC - Analyst : And maybe another one on the ongoing clinical study. So we definitely saw increases, I'm talking about [warts]. So we definitely saw increases in neutrophils across the board. But is there a clinically relevant threshold or the more the merrier or how should we look at this?

Question: Gil Blum - Needham & Company, LLC - Analyst : That's totally fair. So maybe moving on to one of those terms a little bit. The standard of care includes a set of BTK inhibitors, and that is part of your clinical study. How much more of an effect are you looking for with mavorixafor as an added -- as an outcome?

Question: Gil Blum - Needham & Company, LLC - Analyst : Okay. All right, Paula. Thank you very much for attending our -- the presentation today in our conference more broadly. And we look forward to additional updates.